Is Global Health (MEDANTA) overvalued or fairly valued?

MarketChacha shows Global Health's valuation in context — a forward P/E of about 42.0, a price-to-book of about 9.2 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Global Health's revenue?

Global Health reported revenue of ₹4,410 Cr for FY2026, with net profit of ₹556 Cr, per official filings.

What is the share price of Global Health (MEDANTA)?

Global Health last traded at ₹1,353.40 (+1.7% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Global Health

MEDANTA · NSE · Healthcare · India

₹1,353.40+1.7%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 9:59 AM

Snapshot

TickerMEDANTA

ExchangeNSE

SectorHealthcare

IndustryMedical Care Facilities

CountryIndia

HeadquartersGurugram, India

Market cap₹36,368 Cr

P/B9.2

Volume4.91L

Websitewww.medanta.org

Filings tracked0

About Global Health

Global Health Limited, together with its subsidiaries, provides healthcare services in India. The company offers treatments in the areas of digestive and hepatobiliary sciences, cardiac and cancer care, neurosciences, gastrosciences, orthopaedics, renal care, liver transplant, lung transplant, bone marrow transplant, chest surgery, gynaecology and gynaeoncology, paediatric care, obstetrics, emergency, ENT, head and neck surgery, internal medicine, respiratory and sleep medicine, peripheral vascular and endovascular sciences, endocrinology and diabetes, rheumatology and immunology, radiology and imaging, ophthalmology, critical care, dermatology, dentistry, and dietetics and nutrition, as well as plastic, aesthetic, and reconstructive surgery. It also provides second opinion, lab tests and diagnostics, homecare and elder care services, telemedicine and air ambulance services, and e-ICU services, and health plans checkup. In addition, the company is involved in trading of pharmacy and other medical consumables; and medical and healthcare education activities. The company operates a network of hospitals under the Medanta brand. Global Health Limited was incorporated in 2004 and is based in Gurugram, India.

Profile as reported by Yahoo Finance.

Who owns it

Promoters67.1%
Institutions23.9%
Public & other8.9%

68 institutional holders

As reported by Yahoo Finance. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend12.1% → 12.6%

Margin has held broadly steady over the period — stable profitability.

Growth qualityrev 18% · PAT 20%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹1,211 Cr

Next fiscal year

Rev ₹5,944 Cr · EPS 32.25

Est. earnings growth +24.8%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

₹956.0052-wk range₹1,456.50

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 4

Market cap

₹36,368 Cr

Day change

+1.7%

Fwd P/E

42.0

P/B

9.2

Div yield

0.04%

Beta

0.16

Revenue (FY2026)

₹4,410 Cr

Net margin

12.6%

Revenue CAGR (3y)

+17.9%

Profit CAGR (3y)

+19.5%

Net profit (FY2026)

₹556 Cr

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about MEDANTA

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹4,410 Cr	₹556 Cr	12.6%
FY2025	₹3,692 Cr	₹481 Cr	13.0%
FY2024	₹3,275 Cr	₹478 Cr	14.6%
FY2023	₹2,694 Cr	₹326 Cr	12.1%

Quarterly

Period	Revenue	Net profit	Net margin
2026Q1	₹1,159 Cr	₹144 Cr	12.4%
2025Q4	₹1,121 Cr	₹95 Cr	8.5%
2025Q3	₹1,099 Cr	₹158 Cr	14.4%
2025Q2	₹1,031 Cr	₹159 Cr	15.4%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.